

| | | | |
|----------------------------------------------------|------------------------|------------------------|--|
| <i>Examiner-Initiated Interview Summary</i> | Application No. | Applicant(s) | |
| | Examiner | Art Unit | |
| | 12/928,119 | GUENZLER-PUKALL ET AL. | |
| | SAMIRA JEAN-LOUIS | 1627 | |

All participants (applicant, applicant's representative, PTO personnel):

(1) SAMIRA JEAN-LOUIS. (3) ____.

(2) Christopher Turner. (4) ____.

Date of Interview: 05 February 2013.

Type: ☒ Telephonic ☐ Video Conference
 ☐ Personal [copy given to: ☐ applicant ☐ applicant's representative]

Exhibit shown or demonstration conducted: ☐ Yes ☐ No.
 If Yes, brief description: _____.

Issues Discussed ☐ 101 ☒ 112 ☐ 102 ☐ 103 ☐ Others
 (For each of the checked box(es) above, please describe below the issue and detailed description of the discussion)

Claim(s) discussed: 1-3,6 and 7.

Identification of prior art discussed: N/A.

Substance of Interview
 (For each issue discussed, provide a detailed description and indicate if agreement was reached. Some topics may include: identification or clarification of a reference or a portion thereof, claim interpretation, proposed amendments, arguments of any applied references etc...)

The examiner contacted Applicant to discuss potential allowable subject matter. Specifically, the examiner questioned applicant as to where enablement for treating tissue damage was found in the specification. While the examiner contends that applicant demonstrated stabilization of HIF alpha, nowhere in the specification did applicant demonstrate actual treatment of tissue damage as a result of hypoxia or ischemia. Additionally, the examiner contends that because applicant failed to test various compounds that stabilize HIF alpha including the elected species, applicant is also not enabled for the breadth of claim 1. Moreover, the examiner reminds applicant that because of the co-pending applications, terminal disclaimers (TD) on co-pending application 12/811,821; now U.S. Patent 8,269,008 & 8,217,043 will also need to be filed. Applicant stated that they will consider amending the claims and will call back. On 02/12/13, applicant called back and stated that they would consider amending the claims to treatment of hypoxic or ischemic disorders and will consider amending the compound to heterocyclic carboxamide compound that stabilized HIF-alpha since applicant has tested such compounds in the stability of HIF-alpha. The examiner agrees that applicant will be enabled for such claim and will await the filing of the TDs before claims can be issued to allowance .

Applicant recordation instructions: It is not necessary for applicant to provide a separate record of the substance of interview.

Examiner recordation instructions: Examiners must summarize the substance of any interview of record. A complete and proper recordation of the substance of an interview should include the items listed in MPEP 713.04 for complete and proper recordation including the identification of the general thrust of each argument or issue discussed, a general indication of any other pertinent matters discussed regarding patentability and the general results or outcome of the interview, to include an indication as to whether or not agreement was reached on the issues raised.

☐ Attachment

| | |
|--------------------------------------------------------|--|
| /SAMIRA JEAN-LOUIS/ Primary Examiner, Art Unit 1627 | |
|--------------------------------------------------------|--|